SCM
PCRX icon

Schnieders Capital Management’s Pacira BioSciences PCRX Stock Holding History

Schnieders Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,210
Closed -$201K – 153
2017
Q2 		$201K Buy
+4,210
New +$195K 0.09% 149
2016
Q1 		– Sell
-2,800
Closed -$215K – 138
2015
Q4 		$215K Buy
+2,800
New +$159K 0.13% 113

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

Schnieders Capital Management's PCRX Position: Q3 2017 in Review

Schnieders Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2017, closing a stake of 4,210 shares — an estimated $201K sold.

Schnieders Capital Management first reported a position in PCRX in Q4 2015 and held it in 2 quarters. The position peaked at $215K in Q4 2015. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2017.

  • Schnieders Capital Management reported no remaining Pacira BioSciences position as of Q3 2017 after selling out during the quarter.
  • Schnieders Capital Management sold 4,210 Pacira BioSciences shares in Q3 2017, an estimated $201K.
  • Schnieders Capital Management first reported a position in Pacira BioSciences in Q4 2015 and held it in 2 quarters.
  • Schnieders Capital Management's Pacira BioSciences position peaked at $215K in Q4 2015.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2017.

Based on Schnieders Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.